tradingkey.logo

Esperion Therapeutics Inc

ESPR
View Detailed Chart

2.170USD

+0.040+1.88%
Close 08/22, 16:00ETQuotes delayed by 15 min
434.34MMarket Cap
LossP/E TTM

Esperion Therapeutics Inc

2.170

+0.040+1.88%
Intraday
1m
30m
1h
D
W
M
D

Today

+1.88%

5 Days

+5.85%

1 Month

+77.87%

6 Months

+19.23%

Year to Date

-1.36%

1 Year

+26.90%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 8 analysts
BUY
Current Rating
5.800
Target Price
167.28%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

178
Total
5
Median
8
Average
Company name
Ratings
Analysts
Esperion Therapeutics Inc
ESPR
8
Biogen Inc
BIIB
37
Vertex Pharmaceuticals Inc
VRTX
34
Alnylam Pharmaceuticals Inc
ALNY
34
Amgen Inc
AMGN
33
Eli Lilly and Co
LLY
29
1
2
3
...
36

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Strong buy
Sell(0)
Neutral(0)
Buy(11)
Indicators
Sell(0)
Neutral(0)
Buy(5)
Indicators
Value
Direction
MACD(12,26,9)
0.034
Buy
RSI(14)
73.474
Buy
STOCH(KDJ)(9,3,3)
87.285
Overbought
ATR(14)
0.164
Low Volatility
CCI(14)
110.269
Buy
Williams %R
4.918
Overbought
TRIX(12,20)
2.191
Buy
StochRSI(14)
91.946
Buy
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
2.098
Buy
MA10
2.019
Buy
MA20
1.809
Buy
MA50
1.418
Buy
MA100
1.201
Buy
MA200
1.656
Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.
Ticker SymbolESPR
CompanyEsperion Therapeutics Inc
CEOMr. Sheldon L. Koenig
Websitehttps://www.esperion.com/
KeyAI